SUN PHARMA ADV.RES.CO.LTD
SPARC · General/Diversified · NSE
₹161
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SPARC yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
30%
ROE
157.9%
Debt/Equity
0.37
WACC
11.1%
Market Cap
₹5,214 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-667.9%
Return on capital employed
EV / EBITDA
4.6×
Enterprise multiple
Debt / EBITDA
0.3×
Leverage vs earnings
Interest Coverage
-39.1×
EBIT covers interest
Current Ratio
0.07×
Short-term liquidity
Asset Turnover
5.60×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
49.3%
5-year revenue growth
Ratio Trends
SPARC · last 9 annual periods
ROE
157.9%
ROCE
-667.9%
Operating Margin
—
Debt / Equity
0.37×
PE
—
EV / EBITDA
—
Historical Financials
SPARC · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹137 Cr | ₹239 Cr | — | — | ₹1879 Cr | +92.4% |
| EBITDA | ₹-180 Cr | ₹-203 Cr | ₹-373 Cr | ₹-321 Cr | ₹1597 Cr | — |
| EBIT | ₹-190 Cr | ₹-215 Cr | ₹-385 Cr | — | — | — |
| PAT | ₹-203 Cr | ₹-223 Cr | ₹-387 Cr | ₹-343 Cr | ₹1553 Cr | — |
| EPS (diluted) | ₹7.73 | ₹-7.82 | ₹-11.93 | — | — | — |
| CFO | ₹-208 Cr | ₹-69.1 Cr | ₹-429 Cr | ₹-360 Cr | ₹-239 Cr | — |
| CapEx | ₹-32.7 Cr | ₹-15.4 Cr | ₹-26.5 Cr | ₹-10.3 Cr | ₹-23.8 Cr | — |
| FCF | ₹-241 Cr | ₹-84.5 Cr | ₹-456 Cr | ₹-371 Cr | ₹-263 Cr | — |
| Total Assets | ₹280 Cr | ₹830 Cr | ₹515 Cr | ₹336 Cr | ₹2171 Cr | +66.9% |
| Total Debt | ₹79.2 Cr | ₹15.7 Cr | ₹57.7 Cr | ₹265 Cr | ₹559 Cr | +63.0% |
| Shareholders' Equity | ₹31.2 Cr | ₹513 Cr | ₹126 Cr | ₹-217 Cr | ₹1339 Cr | +155.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SPARC vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
INNOVACAP INNOVACAP | — | — | Pending | 12.9% | — |
GUJTHEM GUJTHEM | — | — | Pending | 16.2% | — |
 AARTIDRUGS AARTIDRUGS | — | — | Pending | 12.6% | 15.0× |
 RPGLIFE RPGLIFE | — | — | Pending | 34.5% | — |
 GUFICBIO GUFICBIO | — | — | Pending | 9.7% | 42.8× |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SPARC in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of SPARC →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SPARC →
Compare
Head-to-head with peers
Compare SPARC side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SPARCNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.